Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2946 entries
Sorted by: Best Match Show Resources per page
The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures.

Pharmaceuticals (Basel, Switzerland)

Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S.
PMID: 25244509
Pharmaceuticals (Basel). 2014 Sep 19;7(9):954-89. doi: 10.3390/ph7090954.

At the time of birth, humans experience an induced pro-inflammatory beneficial event. The mediators of this encouraged activity, is a fleet of bacteria that assault all mucosal surfaces as well as the skin. Thus initiating effects that eventually provide...

Cite
Vitetta L, Manuel R, Zhou JY, et al. The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel). 2014;7(9):954-89doi: 10.3390/ph7090954.
Vitetta, L., Manuel, R., Zhou, J. Y., Linnane, A. W., Hall, S., & Coulson, S. (2014). The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel, Switzerland), 7(9), 954-89. https://doi.org/10.3390/ph7090954
Vitetta, Luis, et al. "The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures." Pharmaceuticals (Basel, Switzerland) vol. 7,9 (2014): 954-89. doi: https://doi.org/10.3390/ph7090954
Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel). 2014 Sep 19;7(9):954-89. doi: 10.3390/ph7090954. PMID: 25244509; PMCID: PMC4190499.
Copy Download .nbib Format: NLM
Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.

Pharmaceuticals (Basel, Switzerland)

Darcet F, Gardier AM, Gaillard R, David DJ, Guilloux JP.
PMID: 26901205
Pharmaceuticals (Basel). 2016 Feb 17;9(1). doi: 10.3390/ph9010009.

Major Depressive Disorder (MDD) is the most common psychiatric disease, affecting millions of people worldwide. In addition to the well-defined depressive symptoms, patients suffering from MDD consistently complain about cognitive disturbances, significantly exacerbating the burden of this illness. Among...

Cite
Darcet F, Gardier AM, Gaillard R, et al. Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. Pharmaceuticals (Basel). 2016;9(1)doi: 10.3390/ph9010009.
Darcet, F., Gardier, A. M., Gaillard, R., David, D. J., & Guilloux, J. P. (2016). Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. Pharmaceuticals (Basel, Switzerland), 9(1), . https://doi.org/10.3390/ph9010009
Darcet, Flavie, et al. "Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease." Pharmaceuticals (Basel, Switzerland) vol. 9,1 (2016). doi: https://doi.org/10.3390/ph9010009
Darcet F, Gardier AM, Gaillard R, David DJ, Guilloux JP. Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease. Pharmaceuticals (Basel). 2016 Feb 17;9(1). doi: 10.3390/ph9010009. PMID: 26901205; PMCID: PMC4812373.
Copy Download .nbib Format: NLM
The Role of Immunotherapy in Multiple Myeloma.

Pharmaceuticals (Basel, Switzerland)

Kocoglu M, Badros A.
PMID: 26784207
Pharmaceuticals (Basel). 2016 Jan 14;9(1). doi: 10.3390/ph9010003.

Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs....

Cite
Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel). 2016;9(1)doi: 10.3390/ph9010003.
Kocoglu, M., & Badros, A. (2016). The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel, Switzerland), 9(1), . https://doi.org/10.3390/ph9010003
Kocoglu, Mehmet, and Badros, Ashraf. "The Role of Immunotherapy in Multiple Myeloma." Pharmaceuticals (Basel, Switzerland) vol. 9,1 (2016). doi: https://doi.org/10.3390/ph9010003
Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel). 2016 Jan 14;9(1). doi: 10.3390/ph9010003. PMID: 26784207; PMCID: PMC4812367.
Copy Download .nbib Format: NLM
Perceptions of patient provider agreements.

Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain

Albrecht JS, Khokhar B, Pradel F, Campbell M, Palmer J, Harris I, Palumbo F.
PMID: 27293486
J Pharm Health Serv Res. 2015 Sep;6(3):139-144. doi: 10.1111/jphs.12099. Epub 2015 Jun 16.

OBJECTIVES: Use of patient provider agreements (PPAs) is increasing, yet there is limited evidence on the effectiveness of PPAs to prevent prescription opioid misuse and diversion, and few guidelines for providers. We conducted eight focus groups to understand patient...

Cite
Albrecht JS, Khokhar B, Pradel F, et al. Perceptions of patient provider agreements. J Pharm Health Serv Res. 2015;6(3):139-144doi: 10.1111/jphs.12099.
Albrecht, J. S., Khokhar, B., Pradel, F., Campbell, M., Palmer, J., Harris, I., & Palumbo, F. (2015). Perceptions of patient provider agreements. Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain, 6(3), 139-144. https://doi.org/10.1111/jphs.12099
Albrecht, Jennifer S, et al. "Perceptions of patient provider agreements." Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain vol. 6,3 (2015): 139-144. doi: https://doi.org/10.1111/jphs.12099
Albrecht JS, Khokhar B, Pradel F, Campbell M, Palmer J, Harris I, Palumbo F. Perceptions of patient provider agreements. J Pharm Health Serv Res. 2015 Sep;6(3):139-144. doi: 10.1111/jphs.12099. Epub 2015 Jun 16. PMID: 27293486; PMCID: PMC4902116.
Copy Download .nbib Format: NLM
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.

Pharmaceuticals (Basel, Switzerland)

Sorge CE, McDaniel JK, Xavier AC.
PMID: 27213405
Pharmaceuticals (Basel). 2016 May 19;9(2). doi: 10.3390/ph9020028.

Pediatric Non-Hodgkin Lymphomas (NHL) are a diverse group of malignancies and as such treatment can vary based on the different biological characteristics of each malignancy. Significant advancements are being made in the treatment and outcomes of this group of...

Cite
Sorge CE, McDaniel JK, Xavier AC. Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel). 2016;9(2)doi: 10.3390/ph9020028.
Sorge, C. E., McDaniel, J. K., & Xavier, A. C. (2016). Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel, Switzerland), 9(2), . https://doi.org/10.3390/ph9020028
Sorge, Caryn E, et al. "Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future." Pharmaceuticals (Basel, Switzerland) vol. 9,2 (2016). doi: https://doi.org/10.3390/ph9020028
Sorge CE, McDaniel JK, Xavier AC. Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel). 2016 May 19;9(2). doi: 10.3390/ph9020028. PMID: 27213405; PMCID: PMC4932546.
Copy Download .nbib Format: NLM
Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties.

Pharmaceuticals (Basel, Switzerland)

Liakos IL, Grumezescu AM, Holban AM, Florin I, D'Autilia F, Carzino R, Bianchini P, Athanassiou A.
PMID: 27399724
Pharmaceuticals (Basel). 2016 Jul 07;9(3). doi: 10.3390/ph9030042.

Polylactic acid was combined with lemongrass essential oil (EO) to produce functional nanocapsules (NCs). The obtained polylactic acid nanoparticles showed antimicrobial activity both with and without the presence of lemongrass oil; however, the presence of EO improved the activity...

Cite
Liakos IL, Grumezescu AM, Holban AM, et al. Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties. Pharmaceuticals (Basel). 2016;9(3)doi: 10.3390/ph9030042.
Liakos, I. L., Grumezescu, A. M., Holban, A. M., Florin, I., D'Autilia, F., Carzino, R., Bianchini, P., & Athanassiou, A. (2016). Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties. Pharmaceuticals (Basel, Switzerland), 9(3), . https://doi.org/10.3390/ph9030042
Liakos, Ioannis L, et al. "Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties." Pharmaceuticals (Basel, Switzerland) vol. 9,3 (2016). doi: https://doi.org/10.3390/ph9030042
Liakos IL, Grumezescu AM, Holban AM, Florin I, D'Autilia F, Carzino R, Bianchini P, Athanassiou A. Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties. Pharmaceuticals (Basel). 2016 Jul 07;9(3). doi: 10.3390/ph9030042. PMID: 27399724; PMCID: PMC5039495.
Copy Download .nbib Format: NLM
On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.

Pharmaceuticals (Basel, Switzerland)

Wei Y.
PMID: 26263999
Pharmaceuticals (Basel). 2015 Jul 31;8(3):455-73. doi: 10.3390/ph8030455.

Phosphoprotein enriched in astrocytes, 15 KDa (PEA-15), a ubiquitously expressed small protein in all mammals, is known for decades for its potent interactions with various protein partners along distinct biological pathways. Most notable interacting partners of PEA-15 include extracellular...

Cite
Wei Y. On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel). 2015;8(3):455-73doi: 10.3390/ph8030455.
Wei, Y. (2015). On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel, Switzerland), 8(3), 455-73. https://doi.org/10.3390/ph8030455
Wei, Yufeng. "On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities." Pharmaceuticals (Basel, Switzerland) vol. 8,3 (2015): 455-73. doi: https://doi.org/10.3390/ph8030455
Wei Y. On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities. Pharmaceuticals (Basel). 2015 Jul 31;8(3):455-73. doi: 10.3390/ph8030455. PMID: 26263999; PMCID: PMC4588177.
Copy Download .nbib Format: NLM
Essential Oils and Antifungal Activity.

Pharmaceuticals (Basel, Switzerland)

Nazzaro F, Fratianni F, Coppola R, Feo V.
PMID: 29099084
Pharmaceuticals (Basel). 2017 Nov 02;10(4). doi: 10.3390/ph10040086.

Since ancient times, folk medicine and agro-food science have benefitted from the use of plant derivatives, such as essential oils, to combat different diseases, as well as to preserve food. In Nature, essential oils play a fundamental role in...

Cite
Nazzaro F, Fratianni F, Coppola R, et al. Essential Oils and Antifungal Activity. Pharmaceuticals (Basel). 2017;10(4)doi: 10.3390/ph10040086.
Nazzaro, F., Fratianni, F., Coppola, R., & Feo, V. (2017). Essential Oils and Antifungal Activity. Pharmaceuticals (Basel, Switzerland), 10(4), . https://doi.org/10.3390/ph10040086
Nazzaro, Filomena, et al. "Essential Oils and Antifungal Activity." Pharmaceuticals (Basel, Switzerland) vol. 10,4 (2017). doi: https://doi.org/10.3390/ph10040086
Nazzaro F, Fratianni F, Coppola R, Feo V. Essential Oils and Antifungal Activity. Pharmaceuticals (Basel). 2017 Nov 02;10(4). doi: 10.3390/ph10040086. PMID: 29099084; PMCID: PMC5748643.
Copy Download .nbib Format: NLM
How Efficient Is My (Medicinal) Chemistry?.

Pharmaceuticals (Basel, Switzerland)

Vanden Eynde JJ.
PMID: 27196914
Pharmaceuticals (Basel). 2016 May 16;9(2). doi: 10.3390/ph9020026.

"Greening" a chemical transformation is not about only changing the nature of a solvent or decreasing the reaction temperature. There are metrics enabling a critical quantification of the efficiency of an experimental protocol. Some of them are applied to...

Cite
Vanden Eynde JJ. How Efficient Is My (Medicinal) Chemistry?. Pharmaceuticals (Basel). 2016;9(2)doi: 10.3390/ph9020026.
Vanden Eynde, J. J. (2016). How Efficient Is My (Medicinal) Chemistry?. Pharmaceuticals (Basel, Switzerland), 9(2), . https://doi.org/10.3390/ph9020026
Vanden Eynde, Jean Jacques. "How Efficient Is My (Medicinal) Chemistry?." Pharmaceuticals (Basel, Switzerland) vol. 9,2 (2016). doi: https://doi.org/10.3390/ph9020026
Vanden Eynde JJ. How Efficient Is My (Medicinal) Chemistry?. Pharmaceuticals (Basel). 2016 May 16;9(2). doi: 10.3390/ph9020026. PMID: 27196914; PMCID: PMC4932544.
Copy Download .nbib Format: NLM
Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model.

Pharmaceuticals (Basel, Switzerland)

Vasilevich NI, Tatarskiy VV, Aksenova EA, Kazyulkin DN, Afanasyev II.
PMID: 27089349
Pharmaceuticals (Basel). 2016 Apr 13;9(2). doi: 10.3390/ph9020019.

Based on the data for compounds known from the literature to be active against various types of Ser/Thr kinases, a general pharmachophore model for these types of kinases was developed. The search for the molecules fitting to this pharmacophore...

Cite
Vasilevich NI, Tatarskiy VV, Aksenova EA, et al. Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model. Pharmaceuticals (Basel). 2016;9(2)doi: 10.3390/ph9020019.
Vasilevich, N. I., Tatarskiy, V. V., Aksenova, E. A., Kazyulkin, D. N., & Afanasyev, I. I. (2016). Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model. Pharmaceuticals (Basel, Switzerland), 9(2), . https://doi.org/10.3390/ph9020019
Vasilevich, Natalya I, et al. "Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model." Pharmaceuticals (Basel, Switzerland) vol. 9,2 (2016). doi: https://doi.org/10.3390/ph9020019
Vasilevich NI, Tatarskiy VV, Aksenova EA, Kazyulkin DN, Afanasyev II. Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model. Pharmaceuticals (Basel). 2016 Apr 13;9(2). doi: 10.3390/ph9020019. PMID: 27089349; PMCID: PMC4932537.
Copy Download .nbib Format: NLM
Acorenone B: AChE and BChE Inhibitor as a Major Compound of the Essential Oil Distilled from the Ecuadorian Species Niphogeton dissecta (Benth.) J.F. Macbr.

Pharmaceuticals (Basel, Switzerland)

Calva J, Bec N, Gilardoni G, Larroque C, Cartuche L, Bicchi C, Montesinos JV.
PMID: 29088082
Pharmaceuticals (Basel). 2017 Oct 31;10(4). doi: 10.3390/ph10040084.

This study investigated the chemical composition, physical proprieties, biological activity, and enantiomeric analysis of the essential oil from the aerial parts of

Cite
Calva J, Bec N, Gilardoni G, et al. Acorenone B: AChE and BChE Inhibitor as a Major Compound of the Essential Oil Distilled from the Ecuadorian Species Niphogeton dissecta (Benth.) J.F. Macbr. Pharmaceuticals (Basel). 2017;10(4)doi: 10.3390/ph10040084.
Calva, J., Bec, N., Gilardoni, G., Larroque, C., Cartuche, L., Bicchi, C., & Montesinos, J. V. (2017). Acorenone B: AChE and BChE Inhibitor as a Major Compound of the Essential Oil Distilled from the Ecuadorian Species Niphogeton dissecta (Benth.) J.F. Macbr. Pharmaceuticals (Basel, Switzerland), 10(4), . https://doi.org/10.3390/ph10040084
Calva, James, et al. "Acorenone B: AChE and BChE Inhibitor as a Major Compound of the Essential Oil Distilled from the Ecuadorian Species Niphogeton dissecta (Benth.) J.F. Macbr." Pharmaceuticals (Basel, Switzerland) vol. 10,4 (2017). doi: https://doi.org/10.3390/ph10040084
Calva J, Bec N, Gilardoni G, Larroque C, Cartuche L, Bicchi C, Montesinos JV. Acorenone B: AChE and BChE Inhibitor as a Major Compound of the Essential Oil Distilled from the Ecuadorian Species Niphogeton dissecta (Benth.) J.F. Macbr. Pharmaceuticals (Basel). 2017 Oct 31;10(4). doi: 10.3390/ph10040084. PMID: 29088082; PMCID: PMC5748641.
Copy Download .nbib Format: NLM
Propagation of Fibrillar Structural Forms in Proteins Stopped by Naturally Occurring Short Polypeptide Chain Fragments.

Pharmaceuticals (Basel, Switzerland)

Roterman I, Banach M, Konieczny L.
PMID: 29144442
Pharmaceuticals (Basel). 2017 Nov 16;10(4). doi: 10.3390/ph10040089.

Amyloids characterized by unbounded growth of fibrillar structures cause many pathological processes. Such unbounded propagation is due to the presence of a propagating hydrophobicity field around the fibril's main axis, preventing its closure (unlike in globular proteins). Interestingly, similar...

Cite
Roterman I, Banach M, Konieczny L. Propagation of Fibrillar Structural Forms in Proteins Stopped by Naturally Occurring Short Polypeptide Chain Fragments. Pharmaceuticals (Basel). 2017;10(4)doi: 10.3390/ph10040089.
Roterman, I., Banach, M., & Konieczny, L. (2017). Propagation of Fibrillar Structural Forms in Proteins Stopped by Naturally Occurring Short Polypeptide Chain Fragments. Pharmaceuticals (Basel, Switzerland), 10(4), . https://doi.org/10.3390/ph10040089
Roterman, Irena, et al. "Propagation of Fibrillar Structural Forms in Proteins Stopped by Naturally Occurring Short Polypeptide Chain Fragments." Pharmaceuticals (Basel, Switzerland) vol. 10,4 (2017). doi: https://doi.org/10.3390/ph10040089
Roterman I, Banach M, Konieczny L. Propagation of Fibrillar Structural Forms in Proteins Stopped by Naturally Occurring Short Polypeptide Chain Fragments. Pharmaceuticals (Basel). 2017 Nov 16;10(4). doi: 10.3390/ph10040089. PMID: 29144442; PMCID: PMC5748646.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2946 entries